Motivated to make better drugs
Powered with tumor data
Delivered by machine learning
By uniquely bringing Patient Selection into focus during the early stages of Target Validation.
By using real patients data, we integrate target validation with cohort selection into a single coherent strategy.
We use 100% of Genome Data, both Exome & Dark Genome alterations.
With a wealth of patient-derived tumor data, we can accurately define patient cohorts and select patient-relevant validation model.
Current targeted medicines focus on inhibiting oncogenes that drive tumor growth. However, oncogenes applicable to larger cohorts have already been explored.
Our primary therapeutic strategy is Synthetic Lethality, providing an opportunity to target tumors with inactivated suppressor genes as well as undruggable oncogenes.
read more